INTRODUCTION
Acquisition by cancer cells of a plethora of resistance-conferring genetic alterations greatly limits the clinical utility of most anticancer drugs. Therefore, there is a need to improve the effectiveness of treatment before mutational-acquired resistance prevails. Relapse is driven by a small subpopulation of residual or ''drug-tolerant'' cells, which are traditionally called ''minimal residual disease'' (MRD), that remain viable upon drug exposure, whereas the rest of the cell population is rapidly killed. Recent in vitro findings have indicated that the emergence of these persisters is unlikely due to mutational mechanisms (Menon et al., 2015; Sharma et al., 2010) . Instead, drug tolerance is thought to be caused by the enrichment of a small subpopulation of cancer (stem) cells that is intrinsically refractory to the effects of anti-cancer drugs (Roesch et al., 2013; Trumpp and Wiestler, 2008) . A non-mutually exclusive scenario proposes that the drug-tolerant phenotype is transiently acquired by a small proportion of cancer cells through non-mutational mechanisms (Menon et al., 2015; Sharma et al., 2010; Su et al., 2017) Identification, characterization, and targeting of MRD are likely to improve outcomes and may even lead to cure (Luskin et al., 2018) . Unfortunately, due to major clinical and technical challenges to sampling, much of what we know to date about MRD's biology of solid cancers comes from in vitro studies and, in particular, from investigations of the adaptive response of cultured BRAF mutant melanoma cells to selective BRAF and MEK-inhibitors. One such study showed that uniform upregulation of the melanoma survival oncogene MITF drives an early non-mutational drug tolerance state and that pharmacological suppression of MITF-sensitized melanoma cells to MAPKpathway inhibition (Smith et al., 2016) . Consistently, enhanced MITF expression has been linked to innate/intrinsic resistance (Gopal et al., 2014; Haq et al., 2013a Haq et al., , 2013b Ji et al., 2015; Johannessen et al., 2013; Mü ller et al., 2014; Smith et al., 2013; Van Allen et al., 2014; Wellbrock and Arozarena, 2015) .
In apparent contrast, overwhelming evidence indicates that melanoma cells with a mesenchymal-like or a so-called ''invasive'' gene expression signature, characterized by low levels of MITF and SOX10 and high levels of AXL, are also intrinsically resistant to MAPK-inhibition (Kemper et al., 2014; Konieczkowski et al., 2014; Mü ller et al., 2014; Shaffer et al., 2017; Titz et al., 2016; Verfaillie et al., 2015) . Drug-induced phenotype switching from a ''proliferative'' to an ''invasive'' state was therefore proposed as an alternative route toward drug tolerance and/ or resistance (Kemper et al., 2014) . More recently, adaptive resistance to RAF inhibition was shown to be driven by yet another melanoma subpopulation of slowly dividing cells that express low levels of MITF and high levels of NGFR (FallahiSichani et al., 2017; Su et al., 2017) .
Whether these distinct MITF high and/or MITF low transcriptional states contribute to drug tolerance in vivo and, if so, whether they co-occur within the same lesion is unknown. This is a highly clinically relevant question. Indeed, if distinct subpopulations of drug-tolerant cells can co-emerge within the same MRD, probing the magnitude of cellular heterogeneity and understanding the molecular mechanisms underlying the selection of drugtolerant subpopulations will be essential to inform the rational selection of a second-or a third-line therapy.
Here, we sought to study the biology of solid tumor MRD in a clinically relevant in vivo context. We chose MAPK-targeted therapy of BRAF mutant melanoma as a paradigm. We developed patient-derived xenograft (PDX) models, allowing tracking and isolation of single residual cancer cells and leveraged the power of single-cell transcriptomics to gain insights into drug tolerance dynamics and heterogeneity.
RESULTS

Modeling MRD In Vivo
We established PDXs (i.e., MEL006, MEL015, and MEL007) from BRAF V600E/K mutant melanoma patients who experienced progressive disease and eventually showed marked sensitivity to a BRAF V600E/K inhibitor (i.e., dabrafenib) used either alone or in combination with a MEK (i.e., trametinib) inhibitor ( Figure S1A ). Before establishing the MEL006 cohorts, we dissociated melanoma lesions, and single-cell suspensions were transduced with dsRed-encoding lentiviruses ( Figure 1A ). Once tumors reached a comparable size, mice were exposed to the dabrafenib-trametinib (DT) combination ( Figure 1B ). All treated lesions rapidly shrunk (phase 1) to reach an impalpable size (phase 2) within 15 days. Continuous treatment invariably led to development of resistance (phase 3), indicating the presence of MRD. Although time to resistance substantially varied from mouse to mouse, comparable response rates and median survivals in repeated trials were seen at the population level ( Figure S1B ). We observed similar drug response profiles in the other two PDX models ( Figure S1B ; data not shown). Consistent with mutational events being a key driver of acquired resistance, targeted DNA sequencing identified de novo mutations in the MEK1 and NRAS genes and BRAF amplification in several lesions that acquired the ability to regrow ON treatment ( Figure S1C ). An alternative splicing event at the BRAF locus was also identified in one of these samples. All these events had previously been identified in patients with acquired resistance to MAPK-inhibitors Long et al., 2014) .
To establish the genomic clonal architecture at the single-cell level (Macaulay et al., 2016) , we isolated MEL006 dsRed-positive cells from drug-naive (T0) and MRD (phase 2) and subjected the genomic DNA of individual cells to massively parallel sequencing ( Figure S1D ). As expected, the CN profiles were complex, with clear heterogeneous alterations in chromosomes 2 and 7. This diversity enabled the inference of distinct subpopulations through hierarchical clustering. Critically, the subclonal distribution at T0 and MRD did not differ significantly. Analysis of a larger number of cells by DNA fluorescence in situ hybridization analysis confirmed this finding ( Figure S1E ). These data indicated that MRD is established through a non-mutational adaptive process and that PDXs are well-suited for studying the mechanisms of drug tolerance in vivo.
MRD Comprises both MITF-High and MITF-Low Melanoma Cells
Bulk RNA sequencing (RNA-seq) indicated that the intensity of the overlapping pigmentation/differentiation and MITF-driven gene expression signatures peaked at MRD (phase 2; Figure 1C ). In contrast, both Hoek's and Verfaillie's invasive gene expression signatures decreased upon drug exposure ( Figure 1C ).
MITF immunostaining was rather uniform in drug-naive lesions with most cells exhibiting both diffuse cytoplasmic and nuclear positivity. Consistent with the increase in MITF activity upon MAPK-inhibition, marked nuclear staining was seen in a fraction of the melanoma cells at phase 2 ( Figure 1D ). An increase in pigmentation, which is a likely consequence of increased MITF activity, was also seen in a small proportion of the drug-tolerant melanoma cells ( Figure 1D ). Critically, there was also a large fraction of cells that became completely devoid of any MITF staining at phase 2 ( Figure 1D ). Similar results were obtained with the MEL015 and MEL007 PDX models (data not shown). These data indicated that the adaptive response to MAPK-inhibition is not uniform. Instead, distinct subpopulations that exhibit very different levels of MITF can emerge in vivo within a single MRD lesion.
Single-Cell RNA-Seq Identifies Distinct Drug-Tolerant States To probe the extent of transcriptional state diversity and portray the dynamics of cell-state transition during drug response, we measured a thousand transcriptomes from individual melanoma cells isolated at different time points. The single-cell RNA-seq (scRNA-seq) data, which were processed using a pipeline that was conceptually similar to PAGODA (Fan et al., 2016) , confirmed the emergence of cells exhibiting contrasting levels of MITF activity at phase 2 ( Figure 2A ).
Four distinct melanoma transcriptional states were detected at this time point (Figures 2B and 2C) . One cluster overlapped with the subpopulation of cells exhibiting very high MITF activity and expressed markers of differentiation and pigmentation, such as TRPM1, GPR143, and MLPH ( Figures 2D and 2E ). This ''pigmented'' subpopulation was enriched at phase 1-2 ( Figure 2C ).
One subpopulation associated with expression of markers of an epithelial-to-mesenchymal (EMT) signature and the ''invasive'' melanoma state (Hoek et al., 2008; Verfaillie et al., 2015) , such as SLIT2, BGN or TNC ( Figures 2D and 2E ). These cells exhibited low levels of MITF (Figure 2A ). Unexpectedly, their percentage dropped progressively from T0 to phases 1 and 2, indicating that drug tolerance is not driven by a proliferative to invasive phenotype switch in this particular model (MEL006). Another cluster was characterized by high expression of neural crest stem cell (NCSC) markers, including NGFR, AQP1, or GFRA2 ( Figures 2D and 2E ). Similarly to ''invasive'' cells, NCSCs exhibited very low to undetectable MITF activity ( Figure 2A ). In contrast to the invasive cells, however, these cells sustained high levels of expression and transcriptional activity of the neural crest specifier SOX10 ( Figure S2A ) and their proportion increased upon drug exposure ( Figure 2C ).
Most remaining cells at phase 2 exhibited intermediate MITF activity (Figures 2A and 2B) , and expressed high levels of CD36, SLC7A8, SLC12A7, or DLX5 ( Figure 2D ). These cells also expressed a set of genes upregulated in nutrient-deprived cells ( Figure 2E ), on the basis of which we named them ''starved''-like melanoma cells (SMCs). Critically, SMCs were particularly enriched at phase 1 and, to a lesser extent, phase 2 ( Figure 2C ).
Note that the SMCs were clearly distinct from other MITF intermediate cells, which expressed the classical ''proliferative'' gene signature and were all detected at T0 and resistant (phase 3) lesions (Figures 2A, S2B , and S2C). As expected, these ''proliferative'' melanoma cells expressed genes associated with a recently described cancer cell metabolism signature ( Figure S2D ) (Kim et al., 2016) . In contrast, expression of these metabolic genes was drastically decreased in all drug-tolerant subpopulations, including the SMCs ( Figure S2D ).
We reconstructed the transcriptional dynamic time course and lineage relationships using Monocle (Trapnell et al., 2014) . The cells were distributed along pseudo-temporally ordering paths from ''proliferative'' melanoma cells to MITF high ''pigmented'' cells (differentiation lineage) or to MITF low/negative cells, which either adopted the SOX10 low ''invasive'' or SOX10 high NCSC states (dedifferentiation lineage). The SMCs followed the ''proliferative'' cells and were present at the branching point, thus preceding both end states. This particular cell ordering was further supported by Destiny-based diffusion plots (Angerer et al., 2016) ( Figure S2E ). These data suggest that drug exposure first promotes a transient transition from a ''proliferative'' to a ''starved''-like state from which cells then make the decision to move along a differentiation trajectory to become ''pigmented'' or a dedifferentiation path and to either become NCSCs or invasive. In the case of MEL006, cells favored entry into the NCSC over the invasive state. None of the drug-tolerant states exhibited mitotic activity (data not shown), indicating that acquisition of drug-tolerance may require cells to exit the cell cycle. Notably, both NCSC and SMC subpopulations had drastically decreased in drugresistant tumors (phase 3; Figure 2C ). This observation raised the possibility that these cells either do not directly contribute to resistance or can only do so following transcriptional reprogramming.
MRD Shows Geographic Heterogeneity
To obtain information about the spatial distribution of the various drug-tolerant states we performed immunostaining for the most discriminative markers of the NCSC (i.e., AQP1), SMC (i.e., CD36), pigmented (MLANA, also known as MART-1) and invasive (i.e., AXL) subpopulations. Singlemarker staining confirmed the dramatic increase in the intensity of expression and the number of AQP1+, MLANA+, and CD36+ (but not AXL+) cells in MEL006 MRD (Figures 3A, 3B, .
Only rare AQP1 cells were detected at T0 and in drug-resistant lesions. Note that AQP1 is also expressed in endothelial cells. Co-staining further confirmed that most AQP1-positive detected in MRD were of melanoma origin, as illustrated by their positivity for the marker S100, and that AQP1 and MITF were anti-correlated in these cells ( Figures 3C, 3D , and S3B). In contrast, CD36-and MLANA-positive cells showed high and very high nuclear MITF immunoreactivity, respectively ( Figure 3C ).
Most AQP1-positive melanoma cells also expressed SOX10 and NGFR at phase 2, but not the invasive marker AXL (Figure S3B) . Whereas a fraction (10% to 15%) of melanoma cells was strongly positive for AXL at T0, their occurrence was rarer (<5%) at phase 2. None of the AQP1+ cells expressed the proliferation marker Ki67 ( Figure S3B ).
We used multiplexed immunohistochemistry (IHC) (Tsujikawa et al., 2017) to further visualize the relative spatial distribution of the various drug-tolerant subpopulations ( Figure 3E ). This analysis confirmed that the selected panel of markers was sufficient to discriminate between the various, non-overlapping drugtolerant states. This also confirmed their increased abundance in MRD compared to T0 ( Figure S3C ). To enable quantitative localization of cellular phenotype we utilized a multiparameter cytometric quantification approach via evaluation of chromogenic intensities using single-cell segmentation algorithms Figure S2 and Table S1 . (Tsujikawa et al., 2017) . Thresholds or gates were set for quantification of single-cell based intensity information for each marker and verified by visual confirmation of cell position on the original stain. Using a sequential gating strategy, we identified MLANA+CD36À (pigmented), CD36+MLANAÀ (SMC), and CD36-MLANA-AQP1+NGFR+ (NCSC) cells ( Figure S3D ), all of which were AXL-. Co-staining of both AQP1 and NGFR was required to distinguish the NCSC state from AQP1+ endothelial cells. Importantly, proportional analysis of each cell state confirmed a predominance of AQP1+NGFR+ cells on treatment and that MITF expression is highest in MLANA+, intermediate in CD36+, and absent in AQP1+NGFR+ cells (Figures 3E and S3D) .
Density plots, which show the distribution of the different discriminative markers, revealed specific spatial patterns for the various cell states ( Figure 3F ). Using positional information acquired from the single-cell segmentation we generated violin plots that display the shortest distance between each individual cell to cells of the same state or cells of other states. This analysis revealed that the NCSC subpopulation occurred in clusters (closer to each other than to other states); as did the CD36-positive SMCs. MLANA + cells were closer to the NGFR/AQP1-double positive cells than they were to each other, indicating dispersion of these cells within the NCSC clusters. Melanoma MRD thus exhibits geographic heterogeneity governed by the clustering of drug-tolerant subpopulations.
MRD Composition Exhibits Marked Interpatient Variability
To infer the composition of MRD from very small amounts of input material, we compare mRNA levels of the 6 most discriminative markers for each drug-tolerant state between the treated lesion and its matched drug-naive counterpart, log2 transform and average. In concordance with the sc-RNA-seq and mIHC data, a reproducible increase in the NCSC, SMC and pigmented, but not invasive, subpopulations was detected in MEL006 MRD ( Figure 4A ). A similar analysis predicted a predominant increase in the invasive and pigmented or SMC and pigmented subpopulations in MEL015 and MEL007 MRDs, respectively ( Figure 4A ). Importantly, these predictions were confirmed by mIHC analyses ( Figures S4A-S4C ). Note that in contrast to the NCSC and CD36+ cells, AXL-positive cells did not occur in clusters, but presented a rather dispersed pattern ( Figure S4D ). Together, these data indicated that MRD composition can vary substantially between different PDX models.
To assess the clinical relevance of these findings, we isolated paired tumor materials from drug-naive and biopsy specimens of patients exposed to BRAF/MEK therapy and performed bulk RNA-seq. Strikingly, co-emergence of NCSC, MCS, invasive, and/or pigmented subpopulations was detected in most ''drug-exposed'' biopsies ( Figure 4A ). We also observed marked inter-patient variability. These findings were further validated by mIHC ( Figures 4B and S4E ). Representative images from 5 patient biopsies pre-and on treatment are shown. These images were selected to illustrate the co-occurrence of several drug-tolerant states and the marked interpatient variability. Adaptive tolerance to MAPK-inhibition thus leads to the co-occurrence of (varying combinations of) up to four distinct transcriptional states (i.e., pigmented, SMC, NCSC, and invasive states) within a single MRD.
NCSCs Emerge in MRD through
Cell-State Transition One of the predominant drug-tolerant states in ON-treatment patient biopsies was the NCSC state. Interestingly, the NCSC marker NGFR has been associated with stem-like properties (FallahiSichani et al., 2017; Menon et al., 2015; Redmer et al., 2014; Shaffer et al., 2017) . Consistently, GSEA identified significant similarities between the NCSC signature and quiescent neural stem cell profiles Llorens-Bobadilla et al., 2015) , as well as with other cancer stem cell profiles (Figures 5A , S5A, and S5B). There was also an overlap with a signature from the therapy-resistant glioblastoma proneural subtype (Verhaak et al., 2010) and the drug-persister signature from a lung cancer cell line (Figures 5A, S5A, and S5B) (Sharma et al., 2010) . These data indicated that the NCSC subpopulation may exhibit stem cell-like properties and, as such, may play a prominent role in driving relapse.
To search for NCSCs in a large cohort of human clinical samples we inspected The Cancer Genome Atlas (TCGA) bulk RNA-seq dataset (n = 469). AQP1 and GFRA2 expression was detected in a small subset (<7%) of skin cutaneous melanomas (SKCM; n = 32; Figures S5C and S5D ). Strikingly, expression of most NCSC markers was elevated in all GFRA2 high compared to GFRA2 low samples and vice versa. In contrast, MITF levels were lower in the GFRA2 high samples. Thirty-one out of the 32 GFRA2 high samples were obtained from drug-naive patients, indicating that NCSCs are present in non-negligible amounts in a fraction of untreated melanoma lesions. Importantly, there was no significant association between the presence of these cells and the BRAF, NRAS, or NF1 mutational status. Inspection of publicly available single-cell data (Tirosh et al., 2016) further established the presence of NCSCs (20 of 1,252 melanoma cells), which all exhibited low MITF activity, in various drug-naive metastatic lesions from 4 of 11 patients (Figure 5B) . Our own single-cell data indicated that the NCSC population was present in minute amount (0.58%; 1 of 172 cells) in drug-naive MEL006 lesions. This was further validated by scRNA-seq of a larger number (>4,000) of T0 melanoma cells ( Figure 5C ). Only 24 of 4,352 (0.55%) cells sequenced exhibited the characteristic NCSC transcriptome. The proportion of NCSC increased by 13-fold (7.74%) at phase 1, a time point at which the lesion had only decreased by 50% of its initial volume ( Figure 2C ). Given that cell proliferation drops abruptly during this first drug response phase, emergence of such a high number of NCSCs at phase 1 cannot solely be due to the selection of a rare pre-existing NCSC subpopulation. In contrast, the data established that therapeutically challenged melanoma cells transit into the NCSC state through transcriptional reprogramming.
Transition into the NCSC State Is Cell Autonomous and Reversible
To assess whether emergence of NCSCs upon MAPK inhibition is cancer cell intrinsic, we exposed 2D cultures of MEL006 to near IC 25 concentrations of dabrafenib-trametinib for 10 days. Fluorescence-activated cell sorting (FACS) analysis revealed a 10-fold increase in GFRA2-positive cells in dabrafenib-trametinib-exposed cultures ( Figure 5D ), but not in cells exposed to other cell proliferation inhibitors such as CDK4/6 or mTOR-inhibitors (data not shown). Bulk transcriptome analysis of FACSsorted GFRA2 high cells revealed a striking increase in expression of NCSC markers as compared to the GFRA2 low subpopulation, and GSEA established a significant overlap between the transcriptome of these in-vitro-cultured cells and the NCSCs isolated from PDXs' MRD ( Figures 5E and 5F ). Moreover, singlecell transcriptome analysis of the FACS-sorted GFRA2 high population further confirmed the enrichment in cells harboring the NCSC gene signature ( Figure S5E ). These data indicated that in vitro cultures of MEL006 exposed to MAPK-inhibitors do produce NCSCs.
To further investigate the generality of this effect, and in particular whether emergence of the NCSCs dependents on the genetic background, we exposed a series of short-term melanoma cultures to concurrent BRAF and/or MEK-inhibition (Figures 5G and S5F) . Critically, upregulation of NCSC markers was observed in all BRAF mutant cultures, whether they exhibited a ''proliferative'' (i.e., MM074) or an ''invasive'' profile (i.e., MM029 and MM099). A similar increase was observed in NRAS mutant (i.e., MM052 and MM165) and triple wild-type (i.e., MM163) cultures upon exposure to trametinib (T). Because expression of the NCSC markers was undetectable in some of these cultures (i.e., MM029), these data further supported the possibility that melanoma cells can transit into the NCSC state through phenotype switching, and thus regardless of their initial transcriptional state and driver mutations.
To determine whether the NCSC state is reversible, we exposed MEL006 cells to sub-lethal doses of dabrafenib-trametinib for 4 days and subsequently cultured the cells in presence or absence of drugs ( Figure S5G ). Whereas an upregulation of NCSC markers was observed in drug-exposed cultures, a progressive decrease in expression of these markers was observed following drug removal. In a separate experiment, MEL006 cells were pre-treated for 4 days with dabrafenib-trametinib before GFRA2 high cells were isolated by FACS and allowed to grow for another 4 days in presence or absence of drugs. An EdUincorporation assay was then performed ( Figure 5H ). Whereas GFRA2 high cells remained quiescent under therapeutic pressure, they acquired the ability to proliferate upon drug removal. In keeping, a progressive decrease in the proportion of GFRA2 high -cells was observed in a FACS-enriched population of GFRA2 high cells from the MM052 short-term culture grown in drug-free medium ( Figure S5H ). Note that, as expected, GFRA2
high -cells were significantly less sensitive to dabrafenibtrametinib than GFRA2 low cells ( Figure S5I ). These data demonstrated that MAPK-inhibition induces a quiescent NCSC state, which is transient and reversible. The kinetics of the inter-conversion between GFRA2-high and GFRA2-low cells in culture further supports a model in which transition in and out of the NCSC state is driven by a non-mutational, adaptive reprogramming process. Importantly, NCSCs have the capacity to re-enter the cell cycle and give rise to proliferating (GFRA2-negative) progenies.
RXR Signaling Is a Key Driver of the NCSC State SCENIC is a robust clustering method for the identification of stable cell states from scRNA-seq data based on the underlying gene regulatory networks (GRNs) . This method confirmed the clear distinction between the pigmentation, NCSC, ''invasive,'' ''proliferative'' and SMC states and identified their underlying regulons ( Figures 6A, 6B , S6A, and S6B).
SCENIC predicted a complex regulatory network underlying the NCSC state that is partly driven by SOX transcription factors (TFs), MEF2C and TFAP2B ( Figure 6B ). Consistently, SOX10 levels and activity are high in the NCSCs ( Figure S2A ). Interestingly, MEF2C is a direct transcriptional target of SOX10 (Agarwal et al., 2011) . Moreover, SOX10 and MEF2C physically interact and function cooperatively to activate the MEF2C gene in a feed-forward transcriptional circuit. Interestingly, MEF2C was recently identified as an effector of neural crest development (Hu et al., 2015) . Similarly, TFAP2B (or AP-2b) is also required for the development of the neural crest and its derivatives (Martino et al., 2016) . Another component of this GRN is the retinoid X receptor-g (RXRG; Figure 6B ). IHC confirmed that the majority of AQP1+ cells present in MRD express high nuclear levels of SOX10, MEF2C, TFAP2B, and RXRG ( Figures 6C and S6C) .
Inspection of the GRN highlighted a putative prominent role for RXRG in this network as most of the discriminative NCSC markers, including GFRA2, GFRA3, AQP1, NGFR, and, even, SOX10 were predicted to be direct target of this TF ( Figure 6D ). RXR functions primarily by heterodimerizing with and regulating the activity of a dozen of nuclear receptors (Evans and Mangelsdorf, 2014) . In ''permissive'' heterodimers, such as RXR/PPAR and RXR/LXR, ligand activation of RXR results in transcriptional activation. Certain natural lipids, such as 9-cis retinoic acid, and synthetic compounds, such as bexarotene (B) , selectively and potently activate such transcriptional response. Interestingly, an increase in the proportion of GFRA2-positive cells was observed upon exposure of MEL006 cultures to bexarotene either alone, or in addition with dabrafenib-trametinib ( Figure 7A ). An increase in GFRA2 levels was observed in NRAS mutant and triple wild-type melanoma cultures exposed to both trametinib and bexarotene ( Figures 7B and 7C ). These data indicated that liganded RXR can induce a transcriptional switch toward the NCSC state, and thus regardless of the genetic background and initial transcriptional state. Conversely, pharmacological inhibition of RXR by HX531 (HX), a potent and selective RXR antagonist (Ebisawa et al., 1999) , inhibited the drug-dependent emergence of GFRA2-positive cells ( Figures 7A and S7A) . Together, these data established RXR signaling as a key driver of the NCSC state.
Targeting RXR Signaling Delays Time-to-Disease Progression The possibility to pharmacologically modulate the abundance of the NCSC subpopulation offered the opportunity to test its putative contribution to drug resistance. We used a short-term melanoma culture (MM52) that exhibits a robust increase in NCSCs in response to MAPK-inhibition (i.e., trametinib, or T). Treatment of these cells with HX or bexarotene alone did not induce measurable long-term growth effects. Strikingly, while bexarotene decreased the potency of trametinib, HX-sensitized cells to long-term exposure to the MAPK inhibitor ( Figures 7D and 7E) .
Consistently, whereas HX increased the response rates of MEL006 PDXs to the dabrafenib-trametinib combination, bexarotene administration mitigated their anti-tumor activity ( Figure 7F) . To assess the impact of HX exposure on the MRD composition we performed qRT-PCR and IHC analyses on MRD materials from mice treated with dabrafenib-trametinib and dabrafenib-trametinib+HX. While, as expected, an increase in NCSC markers was observed in MRD isolated from mice treated with dabrafenib-trametinib, this was attenuated upon exposure to the triple combination ( Figures  S7B-S7D) . Consistently, accumulation of AQP1+ cells in dabrafenib-trametinib+HX-treated mice was mitigated compared to mice challenged with dabrafenib-trametinib only. Importantly, concomitant to this drop, an increase in the other three drug-tolerant states, and in particular of the ''invasive'' state, was observed. IHC confirmed the dramatic upregulation of the ''invasive'' marker AXL in MRD from mice treated with the triple combination ( Figures S7B and S7D) .
Strikingly, combining HX with dabrafenib-trametinib produced a significantly longer median progression-free survival (PFS) period compared to the dabrafenib-trametinib treatment and delayed the development of resistance (50 days for dabrafenib-trametinib vs. 94 days for the triple combination; hazard ratio 0.23; 95% confidence interval [CI] 0.070-0.73; p = 0.0004). It is noteworthy that 20% of the PDXs treated with the dabrafenib-trametinib+HX combination never developed resistance under continuous treatment for up to 120 days ( Figure 7G ). This treatment did not cause any relevant adverse reaction or weight loss (data not shown).
DISCUSSION
Preventing disease relapse through the rational targeting of MRD is emerging as a putative salvage strategy for targeted and other cancer therapies (Luskin et al., 2018) . We show herein that this approach is potentially more challenging than previously anticipated from bulk analyses and in vitro culture studies (Sharma et al., 2010; Smith et al., 2016) . Using refined in vivo pre-clinical models of melanoma and patient biopsies, we indeed demonstrate that MRD is not uniform. Instead, MRD features both cellular and geographic heterogeneity.
We found that MRD from BRAF mutant melanoma lesions exposed to concurrent RAF/MEK-inhibition can contain up to 4 distinct drug-tolerant states. These findings illustrate the remarkable phenotypic plasticity of melanoma cells by their ability to escape the deleterious effect of this drug combination through very distinct mechanisms. One mechanism relies on the activation of a robust MITF transcriptional program, which triggers differentiation into highly pigment-producing cells. Another mechanism causes drug-exposed cells to turn on a ''starvation''-like transcriptional program. Pseudo-time ordering methods predict that this is actually the first program that is engaged by the drug-naive, proliferating melanoma cells in response to drug exposure. Another, very distinct, mechanism of drug tolerance relies on the downregulation of MITF activity and induction of dedifferentiation toward either the invasive or the NCSC state. Importantly, although the NCSC and ''invasive'' states are both characterized by loss of MITF and differentiation markers, our scRNA-seq data provide unambiguous evidence that these transcriptional states represent two distinct subpopulations. The MITF low /SOX10 low /AXL high -invasive subpopulation has been extensively described (Hoek et al., 2006 (Hoek et al., , 2008 . These cells harbor a mesenchymal-like phenotype that is well known for its high intrinsic resistance to MAPK therapeutics in in vitro cultures (Konieczkowski et al., 2014; Mü ller et al., 2014; Shaffer et al., 2017; Verfaillie et al., 2015) . An enrichment of this AXL high subpopulation is a common feature of drugresistant melanomas (Konieczkowski et al., 2014; Mü ller et al., 2014) , and AXL-positive cells are rapidly selected upon therapeutic exposure (Boshuizen et al., 2018) . In contrast to the invasive state, the NCSC state has so far only been poorly described. While drug-resistance is often caused by acquisition of specific genetic alterations, we provide evidence that co-emergence of these distinct drug-tolerant states within MRD can be driven by adaptive, non-mutational, events. Moreover, in concordance with a recent study (Su et al., 2017) , our data indicate that acquisition of, at least some, of these drug-tolerant states is the result of a ''Lamarkian induction'' (Huang, 2012; Pisco and Huang, 2015) . We show that the dramatic enrichment of the NCSC subpopulation in MRD only can be due to de novo phenotypic transition toward this particular state through transcriptional reprogramming, as opposed to an enrichment of rare pre-existing cells.
We also describe herein that, in addition to intra-MRD heterogeneity, MRD's phenotypic composition is also subjected to marked interpatient variability. These observations pose several challenges when it comes to the rational targeting of MRD. One can envision two paradigms for targeting MRD. MRD-targeted treatments may be tailored to the particular MRD composition of MEL006 mice treated with dabrafenibtrametinib+B (n = 3), dabrafenib-trametinib alone (n = 9), and dabrafenib-trametinib+HX (n = 9). In the dabrafenib-trametinib+HX-treated group, three mice achieved a complete response. (G) Kaplan-Meier curve for MEL006 mice treated with dabrafenib-trametinib+B (n = 3), dabrafenib-trametinib alone (n = 9), and dabrafenib-trametinib+HX531 (n = 9). Median time to progression was 34, 50, and 94 days, respectively. Log rank (Mantel-Cox) for dabrafenib-trametinib versus dabrafenib-trametinib+HX: p = 0.0004 (***) and hazard ratio (log rank): 0.23 (95% CI, 0.070 -0.73). See also Figure S7. of the individual patient. This will require sampling and characterization of MRD based on a simple method that can be implemented in routine diagnostic laboratories, use small amounts of input material and generate easily interpretable data. We describe a ''deconvolution'' method that is based on bulk RNA analysis, which predicts with accuracy the proportion of each of the four drug-tolerant states within a given MRD. This method could be amenable to the clinic to assess MRD and, ultimately, inform the rational selection of a second-or a third-line therapy. However, we also show that MRD exhibit geographic heterogeneity and therefore sampling from a single site could result in misinterpretation of the true composition in situ. Moreover, independent MRD from the same patient may undergo divergent evolution that leads to distinct therapeutic responses. Finally, invasive sampling methods will be required to analyze MRD from sites such as liver, lung or brain.
In the second, and more favorable, paradigm one universal treatment that is capable of eradicating MRD regardless of its composition may be applied. Note that complete eradication of MRD may not be necessary. There indeed may be some degree of interdependencies between these subpopulations. Also, not all residual cells are able to contribute to the development of a drug-resistant and heterogeneous tumor. For instance, cells that opted for the differentiation trajectory may not be able to re-enter the cell cycle and proliferate into diagnosable relapse. In contrast, targeting the population(s) of cells with stem cell-like properties is clearly necessary and might even be sufficient. Importantly, gene set enrichment analyses indicated that NCSCs are associated with cancer stem cell phenotypic traits. Consistently, we show that the NCSC subpopulation is a key driver of relapse.
SCENIC predicted RXRG as a key driver of the NCSC state. Remarkably, inhibiting this pathway with a pan-RXR antagonist (HX531) blocked the emergence of NCSCs in drug-exposed cultures. Combined with MAPK-targeting agents, the RXR antagonist also decreased the emergence of NCSCs in MRD and significantly delayed the onset of resistance. Importantly, this occurred despite HX only attenuating (but not preventing) emergence of NCSCs and promoting a concomitant increase in the other three drug-tolerant states in MRD. Therefore, these data highlight the critical role of the NCSC population in driving relapse and even raise the possibility that selective and more efficient targeting of the NCSC subpopulation in MRD may offer an effective approach for delaying or even preventing the development of resistance to melanoma targeted therapy. Noteworthy, HX treatment led to a particularly prominent increase in the AXL high invasive subpopulation, the targeting of which is now possible through the use of the antibody-drug conjugate AXL-107-MMAE (Boshuizen et al., 2018) . Therefore, it may be interesting to test whether adding this molecule to the aforementioned treatment regimen provides additional potential clinical benefit.
In conclusion, although our efforts to characterize MRD through single-cell profiling methods have highlighted an underappreciated heterogeneity and interpatient variability, they also demonstrate that a better understanding of the biology of a finite number of drug-tolerant states may constitute one of the next frontiers for improving outcomes among patients who achieve objective anti-tumor responses to specific anticancer drugs.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culturing Cells from dissociated MEL006 tumors and melanoma short term cultures were grown in 5% CO2 at 37 C in F10 supplemented with 10% FBS and 0.25% GlutaMAX. Gender of the patients from whom the short-term cultures were derived (female: 
Patient-derived xenografts
In collaboration with TRACE, patient-derived xenografts (PDX) models were established using tissue from patients undergoing surgery as part of standard-of-care melanoma treatment at the University Hospitals KU Leuven. Written informed consent was obtained from all patients and all procedures involving human samples were approved by the UZ Leuven Medical Ethical Committee (S54185/ S57760/S59199) and carried out in accordance with the principles of the Declaration of Helsinki. PDX models MEL006, MEL015 and MEL007 were derived from a female, male and male patient respectively. All procedures involving animals were performed in accordance with the guidelines of the IACUC and KU Leuven and were carried out within the context of approved project applications P147/2012, P038/2015, P098/2015 and P035/2016. Fresh tumor tissue was collected in transport medium (RPMI1640 medium supplemented with penicillin/streptomycin and amphotericin B). Tumor fragments were subsequently rinsed in phosphate-buffered saline supplemented with penicillin/streptomycin and amphotericin B and cut into small pieces of approximately 3 3 3 x 3 mm 3 . Tumor pieces were implanted subcutaneously in the interscapular fat pad of female SCID-beige mice (Taconic). Sedation and analgesia was performed using ketamine, medetomidine and buprenorphine. After reaching generation 4 (F4), one mouse with a tumor of 1000 mm 3 was sacrificed. This tumor was minced followed by dissociation using collagenase I & IV and trypsin. Cells were resuspended in serum-free DMEM/F12 medium and 250 000 cells were injected in the interscapular fat pad of 8 -16 week old female NMRI nude mice (Taconic). For single cell RNA sequencing purposes, cells were transduced with a lentivirus carrying dsRed. Cells were washed four times before injecting into the interscapular fat pad. For immunohistochemistry, non-dsRed-transduced lesions were used. For FACS, tumors were enzymatically dissociated using the same protocol.
Pharmacologic treatment of mice
Mice with tumors reaching 1000 mm 3 were started on the BRAF-MEK combination via daily oral gavage. BRAF inhibitor dabrafenib and MEK inhibitor trametinib were dissolved in DMSO at a concentration of 30 and 0.3 mg/mL respectively, aliquoted and stored at À80 C. Each day a fresh aliquot was thawed and diluted 1:10 with phosphate-buffered saline. Mice were treated with a capped dose of 600 -6 mg dabrafenib -trametinib respectively in 200 mL total volume. For the dabrafenib-trametinib-bexarotene and dabrafenib-trametinib-HX531 preparation, bexarotene was dissolved at 30 mg/mL and HX531 at 10 mg/dL respectively in combination with dabrafenib and trametinib. Tumor volume was monitored with a caliper and the volume was calculated using the following formula: V = (p/6)*length*width*height. 
Patient samples
METHOD DETAILS Immunohistochemistry
Tumor biopsies were formalin-fixed, paraffin embedded and cut in sections of about 5 mm. Samples were deparaffinized and dehydrated with xylene and graded alcohols, and subsequently rehydrated with demineralized water. Immunostainings were performed with antibodies listed in the Key Resources Table. Fontana-Masson silver method histochemistry was performed with working silver solution and fast red counterstain. Image acquisition over larger areas of multiple continuous fields involved tiling and stitching performed with ZEN2 software after scanning with a Zeiss Axio Scan Z1 using x20 and x40 objectives. Microscopy images were brightness and contrast adjusted.
FACS
Cells were incubated with GFRA2 antibody AF429 (STAR Methods) for 45 minutes at room temperature, followed by a secondary antibody conjugated with Alexa Fluorâ 594 (STAR Methods) for 30 min at room temperature. Cells were resuspended in FACS sorting buffer (culture medium supplied with 5% serum and 2 mM EDTA). FACS analyses were performed with BD FACSAria III and FlowJoâ software.
FC-131-1096) with volumes reduced by one-tenth on a Labcyte Echo 525 liquid handling robot (Labcyte). After PCR, all samples were pooled and purified using AMPure XP beads at a 0.6x ratio. Library pools were eluted in buffer EB and quality control performed using an Agilent 2100 BioAnalyzer and High Sensitivity DNA chip before adjusting to a concentration of 4nM. The diluted pools were quantified using a KAPA qPCR library quantification kit 480 (Roche 7960140001) on a LightCycler 480 before a final dilution to 1.5nM. Sequencing was performed on HiSeq4000 with 50bp single-end reads.
Single-cell DNA analysis Sequencing reads were aligned to the GRCh37 human reference using Burrows-Wheeler Aligner (BWA). LogR values were calculated for genomic bins of 500,000 uniquely mappable positions, maintaining unique reads with a minimum mapping quality of 30 (Baslan et al., 2012) . A value of 1 was added to each bin's single-cell read count and bins with a %GC content less than 28% were discarded. The bin counts were then transformed by taking the log2 ratio (logR) per bin by dividing the read count of a given bin by the median read count of the bins genome-wide. LogR values were corrected for GC bias using a Loess fit and normalized to the median of the genome-wide logR value. The normalized LogR values were finally segmented using piecewise constant fitting (with the penalty parameter g set to 15). Cells with a median absolute pairwise difference (MAPD) greater than 0.6 were discarded from the analysis resulting in 95 T0 and 84 phase 2-cells passing quality control.
Dropseq (10x Genomics)
We loaded $8,700 cells into one channel of the Chromium system using the v2 single cell reagent kit (10X Genomics). Following capture and lysis, we synthesized cDNA and amplified for 12 cycles. The amplified cDNA was used to construct Illumina sequencing libraries that were each sequenced on an Illumina Nextseq500.
Multiplexed, Sequential Immunohistochemistry and Analysis
Sequential chromogenic immunohistochemistry was performed as previously described (Tsujikawa et al., 2017) , using a modified protocol. In brief, 5 mm FFPE tissue sections of human primary melanoma were de-paraffinized and subsequently stained with hematoxylin (GHS116, Sigma-Aldrich) to visualize nuclei. Following whole-tissue scanning using Aperio ImageScope AT (Leica Biosystems), iterative cycles of standard IHC were performed followed by detection with ImmPressTM IgG-polymerized peroxidase reagents (Vector Laboratories) and visualization with AEC (Vector Laboratories). After whole tissue scanning, AEC was removed using ethanol, antibody was stripped in heated citrate buffer, and the next staining cycle with the next primary antibody was performed. Serial digitized images were processed using a computational image analysis workflow described previously (Tsujikawa et al., 2017) to align and visualize several markers simultaneously in a single pseudo-colored image. From whole-tissue serial images rectangular regions of interest with an area of 6.25 mm 2 were selected.
QUANTIFICATION AND STATISTICAL ANALYSIS
Quantification of gene sets per single cell We used AUCell to quantify our different gene sets per single cell . Briefly, the AUCell output is the gene set 'activity' in each cell (score: 0-1). AUCell calculates the enrichment of the gene sets as an area under the recovery curve (AUC) across the ranking of all genes in a particular cell, whereby genes are ranked by their expression value. This method is independent of the gene expression units and the normalization procedure. AUCell then uses the AUC to calculate whether a critical subset of the input gene set is enriched at the top of the ranking for each cell. In this way, the AUC represents the proportion of expressed genes in the signature and their relative expression values compared to the other genes within the cell (R-packages: SCENIC version 0.1.5, which corresponds to GENIE3 0.99.3, RcisTarget 0.99.0 and AUCell 0.99.5).
Sequential chromogenic immunohistochemistry
Single-cell segmentation and quantification of staining intensity was performed using a CellProfiler v.2.1.1 pipeline. Pixel intensity and shape-size measurements were compatibility with image cytometry data analysis software, FCS Express 5 Image Cytometry v.5.01.0029 (De Novo Software) used for setting gate thresholds for subsequent analysis. Figures 3B, 3D , 5H, 6C, S3B, S4B, and S7D were manually counted by an independent expert to allow for the exclusion of AQP1-expressing endothelial cells on morphological grounds. Panels associated with these AQP1 quantifications were processed identically for reasons of consistency. Figure 5H was quantified using Fiji software to manually count EdU positive cells and to determine total numbers of nuclei per field.
Single and double immunostainings
Statistical analyses
Statistical comparisons in Figures 1C, 5H , and 7A were carried out using the non-parametric Mann-Whitney test. The statistical comparison in Figure 6A was done using the hypergeometric distribution test and the Mantel-Cox log-rank test was used to statistically compare time to progression in Figure 7G . Throughout all figures: significance was concluded at p < 0.05 (*p < 0.05, **p < 0.01, and ***p < 0.001).
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNA and DNaseq data reported in this paper is GEO: GSE116237.
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Supplemental Figures Figure S1 . Establishment of Melanoma PDX Models and Their Response to BRAF&MEK Inhibition, Related to Figure 1 
